Trial Data Show Extended Benefit With Inebilizumab in Myasthenia Gravis

(MedPage Today) — Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting…